Equities Analysts Offer Predictions for MOLN FY2026 Earnings

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) – Stock analysts at HC Wainwright increased their FY2026 EPS estimates for Molecular Partners in a research report issued on Monday, November 2nd. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($1.67) per share for the year, up from their prior estimate of ($1.81). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Molecular Partners’ current full-year earnings is ($1.28) per share. HC Wainwright also issued estimates for Molecular Partners’ Q4 2026 earnings at ($0.44) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.39) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.35) EPS and FY2027 earnings at ($1.51) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, October 2nd. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $8.38.

Molecular Partners Stock Performance

Shares of NASDAQ MOLN opened at $3.19 on Wednesday. The stock’s 50-day simple moving average is $3.99 and its 200-day simple moving average is $4.17. The firm has a market capitalization of $128.77 million, a PE ratio of -1.90 and a beta of 1.17. Molecular Partners has a fifty-two week low of $3.09 and a fifty-two week high of $5.36.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings results on Thursday, October 29th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.08.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biotechnology company headquartered in Schlieren, Switzerland. The company develops therapeutic molecules based on its proprietary DARPin platform, which uses designed ankyrin repeat proteins to create targeted, multi-specific medicines intended to address complex disease pathways.

Molecular Partners’ research and development activities have focused primarily on oncology, ophthalmology and infectious diseases. Its pipeline has included experimental programs designed to engage multiple biological targets, with the goal of improving treatment effectiveness and addressing limitations associated with conventional antibody-based therapies.